ArticleNeurology. Genetics2025
Phenotype-Genotype Correlations in Early-Onset Myelin Protein Zero-Related Neuropathies.
Article in Neurology. Genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Myelin protein zero (MPZ)-related neuropathies include demyelinating CMT1B and later-onset axonal forms (CMT2I/J). CMT1B pathogenic variants act through gain-of-function, destabilizing MPZ and activating the unfolded protein response (UPR), or loss-of-function, disrupting MPZ homomeric interactions in myelin. This study investigates early-onset (<18 years) CMT1B due to MPZ variants in a large Italian cohort, shedding light on clinical progression and genotype-phenotype correlations, with relevance to emerging UPR-targeted therapies. Methods: We analyzed cross-sectional clinical and genetic data from 75 patients across 7 Italian centers. MPZ variants were categorized as destabilizing or non-destabilizing based on published data. To explore the relationship between the degree of protein destabilization and clinical severity, missense variants were evaluated for stability alterations using the DUET online tool, with negative ∆∆G values indicating greater destabilization. Statistical correlations between clinical and molecular features were assessed. Results: This study presents a comprehensive clinical characterization of one of the largest cohorts of early-onset MPZ-related neuropathies reported to date. The Charcot-Marie-Tooth Examination Score (CMTES) correlated with age at assessment ( Discussion: Stratification of MPZ variants into destabilizing and non-destabilizing is crucial for predicting severity and prognosis and tailoring therapeutic strategies. This approach has significant implications for upcoming UPR-modulating treatments and underscores the necessity of integrating molecular and clinical insights for optimal patient care.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.